Activating SRC mutation in a subset of advanced human colon cancers
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers. c-Src has been found to be highly activated in colon cancers, particularly in those metastatic to the liver. Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region. We report here the identification of a truncating mutation in SRC at codon 531 in 12% of cases of advanced human colon cancer tested and demonstrate that the mutation is activating, transforming, tumorigenic and promotes metastasis. These results provide, for the first time, genetic evidence that activating SRC mutations may have a role in the malignant progression of human colon cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundIdentification of a transformation-specific antigen induced by an avian sarcoma virus
BRUGGE, J. S., & ERIKSON, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 888
Kmiecik, T. E., & Shalloway, D. (1987) · Cell · doi:10.1016/0092-8674(87)90756-2 · Cited by 623
Tyr 527 Is Phosphorylated in pp60 c- src : Implications for Regulation
Cooper, J. A., Gould, K. L., Cartwright, C. A., & Hunter, T. (1986) · Science · doi:10.1126/science.2420005 · Cited by 540 · cited 1×
“We targeted this region for mutational screening because it is known to contain the principal regulatory phosphotyrosine (Tyr 530; Ref”
BackgroundThe when and how of Src regulation
Cooper, J. A., & Howell, B. (1993) · Cell · doi:10.1016/0092-8674(93)90634-3 · Cited by 533
Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src
Piwnica-Worms, H., Saunders, K. B., Roberts, T. M., Smith, A. E., & Cheng, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90757-4 · Cited by 520
Cell Transformation by the Viral src Oncogene
Jove, R., & Hanafusa, H. (1987) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.03.110187.000335 · Cited by 401
Self-citationIncrease in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Cited by
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
“…homolog 1 (AKT1), class I phosphatidyl-inositol 3-kinases (PI3Ks) and phosphoinositide-dependent protein kinase 1 (PDPK1) (Slamon et al , 1987; Irby et al , 1999; Shayesteh et al , 1999; Ma et al , 2000; Paez et al , 2004; Stephens et al , 2004; Carpten et al , 2007; Sen & Johnson, 2011;…”
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Self-citationRole of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857
“Using a very sensitive, mutant allele-speci®c assay, a single base pair C-T transition was found in a subset of colon cancer liver metastases and advanced colon cancer primary lesions (Irby et al., 1999).”
BackgroundMethodInfluentialSelf-citationStem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
“[14,39] indicate that c-Src activity is important for proliferation and growth of primary tumors derived from human colon cancer cells.”
BackgroundSrc kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
“In humans, activating mutations of the C-SRC gene have been identified in advanced human colon cancers (Irby et al., 1999).”
Backgroundc-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617
Martin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599
The interplay between Src and integrins in normal and tumor biology
Playford, M. P., & Schaller, M. D. (2004) · Oncogene · doi:10.1038/sj.onc.1208080 · Cited by 523
Clinical, Cellular, and Molecular Aspects of Cancer Invasion
Mareel, M., & Leroy, A. (2003) · Physiological Reviews · doi:10.1152/physrev.00024.2002 · Cited by 524
“Such activating mutations are found in human cancer both in early and late stages of development (72, 180).”
BackgroundGiannoni, E., Buricchi, F., Raugei, G., Ramponi, G., & Chiarugi, P. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6391-6403.2005 · Cited by 455
“In addition, in metastases of human colon cancer, c-Src acquires transforming ability due to mutations at the Tyr527 site (20, 25).”
BackgroundSelected glimpses into the activation and function of Src kinase
Bjorge, J. D., Jakymiw, A., & Fujita, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203923 · Cited by 412
“Recently, a c-src mutation that results in an activated, truncated form of human c-Src, that ends with Tyr530, has been identi®ed in highly metastatic forms of colon carcinoma (Irby et al., 1999).”
BackgroundSelf-citationThe genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
Chung, D. C. (2000) · Gastroenterology · doi:10.1053/gast.2000.16507 · Cited by 414
Src Family Tyrosine Kinases and Growth Factor Signaling
Abram, C. L., & Courtneidge, S. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4732 · Cited by 391
Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling
Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M. A., Brunton, V. G., & Frame, M. C. (2002) · Nature Cell Biology · doi:10.1038/ncb829 · Cited by 362
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Newest findings on the oldest oncogene; how activated src does it
Frame, M. C. (2004) · Journal of Cell Science · doi:10.1242/jcs.01111 · Cited by 367
“These findings are relevant to cancer, since it is reported that oncogenic mutations in Src arise in a subset of advanced human colon cancers tumours (Irby et al., 1999), although it is not yet clear that mutation is the most common mode of Src activation in tumours.”
BackgroundThe Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
“Furthermore, a number of investigators have shown that mutations leading to the constitutive activation of Src in human cancers are rare [15–19].”
BackgroundSrc family kinases: Regulation of their activities, levels and identification of new pathways
Ingley, E. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.012 · Cited by 335
Johnson, F. M., Saigal, B., Talpaz, M., & Donato, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0757 · Cited by 333
“disease progression (3), although activating mutations are rare (5).”
BackgroundBjorge, J. D., Pang, A., & Fujita, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004852200 · Cited by 316
Self-citationLiu, B. A., Jablonowski, K., Raina, M., Arcé, M., Pawson, T., & Nash, P. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.001 · Cited by 294
Lu, Y., Yu, Q., Liu, J. H., Zhang, J., Wang, H., Koul, D., McMurray, J. S., Fang, X., Yung, W. K. A., Siminovitch, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303621200 · Cited by 261
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251
“In a subset of hepatic colorectal carcinoma metastases, Irby et al.34 reported a truncating mutation at codon 531 in 12% of the samples they analyzed.”
BackgroundHIF-1: Using Two Hands to Flip the Angiogenic Switch
Semenza, G. L. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026544214667 · Cited by 248
“Mutant C-SRC, which is found in advanced colon cancers [58], may stimulate VEGF expression [59] via this mechanism.”
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
The C2 Domain of PKCδ Is a Phosphotyrosine Binding Domain
Benes, C. H., Wu, N., Elia, A. E. H., Dharia, T., Cantley, L. C., & Soltoff, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.019 · Cited by 246
“In the majority of colon cancers, Src activity is upregulated, either by increases in its specific activity or levels of expression (Irby et al., 1997; Irby et al., 1999; Malek et al., 2002; Mao et al., 1997).”
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
“However, there is only very limited evidence supporting mutated, constitutively active Src in human epithelial cancers (Irby et al., 1999), where de-regulation appears predominantly driven through post-translational modifications and intracellular interactions be-tween Src and various activated…”
Regulation of Src Family Kinases in Human Cancers
Sen, B., & Johnson, F. M. (2011) · Journal of Signal Transduction · doi:10.1155/2011/865819 · Cited by 228
“Rare activating mutations in Src that are truncated at codon 531 have been reported in some cases of advanced colon cancer patients [64].”
BackgroundUnni, E., Sun, S., Nan, B., McPhaul, M. J., Cheskis, B., Mancini, M. A., & Marcelli, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1121 · Cited by 229
Obesity, the PI3K/Akt signal pathway and colon cancer
Huang, X., & Chen, J. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00607.x · Cited by 224
“The activation of PI3K/Akt in colon cancer has been explained by the activation of its upstream protein tyrosine kinase Src (7).”
BackgroundSrc activation regulates anoikis in human colon tumor cell lines
Windham, T. C., Parikh, N. U., Siwak, D. R., Summy, J. M., McConkey, D. J., Kraker, A. J., & Gallick, G. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205989 · Cited by 217
“Increased specific activity of Src, whether due to infrequent mutation (Irby et al., 1999) or other mechanisms such as altered protein/protein association, is a hallmark of most colon tumors (Bolen et al., 1987; Cartwright et al., 1989; Talamonti et al., 1993).”
BackgroundSRC: A Century of Science Brought to the Clinic
Aleshin, A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 211
“However, similar activating mutations are rare in human tumors, with just one published report that found activating SRCmutations in approximately 12% of human colon cancers [5].”
BackgroundBrunton, V. G., Avizienyte, E., Fincham, V. J., Serrels, B., Metcalf, C. A., Sawyer, T. K., & Frame, M. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1949 · Cited by 213
“Although activating mutations of Src have been reported in a small subset of metastatic tumors (10), this does not seem to be the predominant mechanism of Src activation in tumors (11, 12).”
BackgroundDifferent mechanisms in the tumorigenesis of proximal and distal colon cancers
Lindblom, A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200101000-00013 · Cited by 212
Mechanisms of Selective Autophagy in Normal Physiology and Cancer
Mancias, J. D., & Kimmelman, A. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.027 · Cited by 196
Functions of the Lyn tyrosine kinase in health and disease
Ingley, E. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-21 · Cited by 181
“While only a few instances have found them to be genetically altered in solid cancer [102], their activity/levels, as illustrated recently [103], are commonly altered.”
BackgroundThe role of Src in prostate cancer
Fizazi, K. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm086 · Cited by 183
“Src may be aberrantly activated because of naturally occurring mutations [24, 25], although other studies have failed to detect these mutations, indicating that this cause of Src activation may be rare [26–29].”
BackgroundAutophagic targeting of Src promotes cancer cell survival following reduced FAK signalling
Sandilands, E., Serrels, B., McEwan, D. G., Morton, J. P., Macagno, J. P., McLeod, K., Stevens, C., Brunton, V. G., Langdon, W. Y., Vidal, M., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2386 · Cited by 180
Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2
Fischer, H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.875 · Cited by 180
Colorectal Cancers: An Update on Their Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10010026 · Cited by 174
“TOMM34 is frequently overexpressed in CRCs and is involved in the growth of CRC cells [32], whereas SRC encodes a non-receptor tyrosine kinase that is implicated in colorectal carcinogenesis [33].”
BackgroundHauck, C. R. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf631 · Cited by 181
Pichot, C. S., Hartig, S. M., Xia, L., Arvanitis, C., Monisvais, D., Lee, F. Y., Frost, J. A., & Corey, S. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605101 · Cited by 173
“Aberrant expression or activation of Src family kinases causes perturbation of these activities, leading to transformation and progression of malignant disease (Irby et al, 1997, 1999; Dehm and Bonham, 2004; Gallick, 2004).”
BackgroundRegulation of cell structure and function by actin‐binding proteins: Villin's perspective
Khurana, S., & George, S. P. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.040 · Cited by 171
Ren, Y., Meng, S., Mei, L., Zhao, Z. J., Jove, R., & Wu, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312575200 · Cited by 171
Self-citationNoonberg, S. B., & Benz, C. C. (2000) · Drugs · doi:10.2165/00003495-200059040-00003 · Cited by 173
“[24] Mutational activation of c-src has also been recently reported in a subset of colon cancers.[25] Thus, substantial evidence points to an intimate relationship between the signalling ability of tyrosine kinases and the initiation, growth and metastases of many human tumours.”
BackgroundSRC gene expression in human cancer: the role of transcriptional activation
Dehm, S. M., & Bonham, K. (2004) · Biochemistry and Cell Biology · doi:10.1139/o03-077 · Cited by 165
“More recent studies at the level of the SRC gene, however, have identified mutation (Irby et al. 1999) and transcriptional activation (Dehm et al.”
BackgroundPTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation
Zhu, S., Bjorge, J. D., & Fujita, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4338 · Cited by 168
“In one subset of advanced human colon cancers, increased Srcspecific activity has been linked to a mutation in the COOHterminal regulatory domain of Src (8).”
BackgroundInfluentialSelf-citationOwens, D. W., McLean, G. W., Wyke, A. W., Paraskeva, C., Parkinson, E. K., Frame, M. C., & Brunton, V. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.1.51 · Cited by 158
“In this regard, activating mutations of the c-src gene have recently been associated with late-stage human colorectal cancers (Irby et al., 1999).”
BackgroundBiology of colorectal liver metastases: A review
Bird, N. C., MANGNALL, D., & Majeed, A. W. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20558 · Cited by 172
Forget, A., Martignetti, L., Puget, S., Calzone, L., Brabetz, S., Picard, D., Montagud, A., Liva, S., Sta, A., Dingli, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.002 · Cited by 142
“5 developing cerebella with cis element-flanked genes encoding C-terminal truncated SRC protein (Irby et al., 1999; Ishizawar and Parsons, 2004; Sugimura et al., 2000), constitutively active, SRC-CA, and either EGFP or luciferase (pT2K CAGGS SRC-CA-IRES-EGFP/Luciferase), with pT2K DNp53-copGFP and the Tol2 transposase…”
BackgroundTurro, E., Greene, D., Wijgaerts, A., Thys, C., Lentaigne, C., Bariana, T. K., Westbury, S. K., Kelly, A. M., Selleslag, D., Stephens, J. C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7666 · Cited by 144
Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D., & Moore, C. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00405-6 · Cited by 148
Bao, J., Gur, G., & Yarden, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437945100 · Cited by 136
Tsai, Y.-L., Ha, D. P., Zhao, H., Carlos, A. J., Wei, S., Pun, T. K., Wu, K., Zandi, E., Kelly, K., & Lee, A. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714866115 · Cited by 132
“In HeLa cells, we observed that Tg treatment and the expression of SRC531, F-GRP78, or HA-CD109 all suppressed TGF-β–induced Smad2 phosphorylation (pSmad2) (Fig.”
BackgroundInfluentialAdhesion signaling by a novel mitotic substrate of src kinases
Bhatt, A. S., Erdjument‐Bromage, H., Tempst, P., Craik, C. S., & Moasser, M. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208582 · Cited by 135
Integrins and Signal Transduction
Cabodi, S., Stefano, P. D., Leal, M. D. P. C., Tinnirello, A. A., Bisarò, B., Morello, V., Damiano, L., Aramu, S., Repetto, D., Tornillo, G., et al. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6066-5_5 · Cited by 152
Benlimame, N., He, Q., Su, J., Xiao, D., Xu, Y., Loignon, M., Schlaepfer, D. D., & Alaoui‐Jamali, M. A. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504124 · Cited by 134
“HRG was shown to up-regulate the Tyr215 of c-Src and to increases Src kinase activity, and increased Src activity is associated with reduced cell–cell adhesion (Hamaguchi et al., 1993) and increased metastatic potential (Irby et al., 1999).”
BackgroundDasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“Additional studies by Irby et al cited that activating mutations in Src, as compared to increased expression and activity of Src, in a subset of human colorectal cancers might have a role in the malignant progression of human CRC (Irby et al., 1999).”
BackgroundFaecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer
Hardt, P. D., Mazurek, S., Toepler, M., Schlierbach, P., Bretzel, R. G., EIGENBRODT, E., & Kloer, H. U. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602033 · Cited by 144
“Interestingly, pp60c src kinase and A-Raf are consistently altered in gastrointestinal tumours (Bolen et al, 1987; Iravani et al, 1998; Irby et al, 1999; Luckett et al, 2000; Dehm et al, 2001; Dhillon et al, 2003).”
BackgroundTargeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
Ahluwalia, M. S., de Groot, J., Liu, W., & Gladson, C. L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.014 · Cited by 139
“In a very small subset of colon cancers an activating mutation of c-SRC at codon 531 has been described; however, the presence of this mutation in the population studied (a Chinese population) did not correlate with an increased risk of developing colon cancer [[51, 52]].”
BackgroundSmall molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 136
“In addition, mutations of Met and Src have also been detected in human tumours [53,68].”
BackgroundThe Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 141
“An activating mutation of the Src gene is found in 12% of patients.(8,9) This mutation accounts for only a”
BackgroundDeath‐associated protein kinase (DAPK) and signal transduction: regulation in cancer
Michie, A. M., McCaig, A. M., Nakagawa, R., & Vukovic, M. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07414.x · Cited by 121
Ubiquitin-dependent degradation of active Src
Hakak, Y., & Martin, G. S. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80453-9 · Cited by 126
Ernst, M., Inglese, M., Scholz, G. M., Harder, K. W., Clay, F. J., Bozinovski, S., Waring, P. M., Darwiche, R., Kay, T., Sly, P. D., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020873 · Cited by 131
“Based on documented evidence for rarely occurring activating somatic nonsense mutations in the COOH-terminal end of human c-Src (66, 67), it is tempting to speculate that the hck gene might represent a potential candidate susceptibility locus in addition to those associated with allergy and bronchial hyperresponsivene…”
BackgroundSerrels, A., Macpherson, I. R. J., Evans, T. R. J., Lee, F. Y., Clark, E. A., Sansom, O. J., Ashton, G. H., Frame, M. C., & Brunton, V. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0382 · Cited by 124
Irby, R., & Yeatman, T. J. (2002) · PubMed · Cited by 125
Self-citationSrc kinase contributes to the metastatic spread of carcinoma cells
Boyer, B., Bourgeois, Y., & Poupon, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205298 · Cited by 123
“Accordingly, transfection of normal ®broblasts with a construct coding for an activating mutant of Src leads to increased growth of the derived tumor (Irby et al., 1999).”
BackgroundTsao, A. S., He, D., Saigal, B., Liu, S., Lee, J. J., Bakkannagari, S., Ordóǹez, N. G., Hong, W. K., Wistuba, I. I., & Johnson, F. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0052 · Cited by 126
Src redox regulation: Again in the front line
Giannoni, E., Taddei, M. L., & Chiarugi, P. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.04.025 · Cited by 125
Oxidative Stress Induces Protein Kinase D Activation in Intact Cells
Waldron, R. T., & Rozengurt, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908959199 · Cited by 121
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Moasser, M. M., Srethapakdi, M., Sachar, K. S., Kraker, A. J., & Rosen, N. X. (1999) · PubMed · Cited by 118
Schrage, Y. M., Bruijn, I. H. B., de Miranda, N. F. C. C., van Oosterwijk, J. G., Taminiau, A. H. M., van Wezel, T., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4801 · Cited by 117
“Mutations in Src are involved in the malignant progression of colorectal cancer (27).”
BackgroundAdhesion-linked kinases in cancer; emphasis on Src, focal adhesion kinase and PI 3-kinase
Jones, R. J., Brunton, V., & Frame, M. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00153-2 · Cited by 128
“In addition, expression of v-src, or activated c-src, can confer on cells the ability to colonise the mouse lung when injected into the tail vein [35,36].”
BackgroundThe Lipid Raft-Anchored Adaptor Protein Cbp Controls the Oncogenic Potential of c-Src
Oneyama, C., Hikita, T., Enya, K., Dobenecker, M.-W., Saito, K., Nada, S., Tarakhovsky, A., & Okada, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.026 · Cited by 116
BRK/Sik expression in the gastrointestinal tract and in colon tumors.
Llor, X., Serfas, M. S., Bie, W., Vasioukhin, V. I., Polonskaia, M., Derry, J. M. J., Abbott, C. M., & Tyner, A. L. (1999) · PubMed · Cited by 115
Leroy, C., Fialin, C., Sirvent, A., Simon, V., Urbach, S., Poncet, J., Robert, B., Jouin, P., & Roche, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2354 · Cited by 114
“An activating mutation has been reported in a minority of advanced tumors, suggesting the existence of alternative mechanisms for kinase deregulation (4).”
Backgroundpp60c-src activation in lung adenocarcinoma
Masaki, T., Igarashi, K., Tokuda, M., Yukimasa, S., Han, F., Jin, Y. J., Li, J. Q., Yoneyama, H., Uchida, N., Fujita, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00276-4 · Cited by 114
Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases
Chong, Y., Ia, K. K., Mulhern, T. D., & Cheng, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.027 · Cited by 123
Koppikar, P., Choi, S.-H., Egloff, A. M., Cai, Q., Suzuki, S., Freilino, M., Nozawa, H., Thomas, S. M., Gooding, W. E., Siegfried, J. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5226 · Cited by 115
Coluccia, A. M. L., Benati, D., Dekhil, H., De Filippo, A., Lan, C., & Gambacorti-Passerini, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2057 · Cited by 113
Morel, J. C. M., Park, C. C., Zhu, K., Kumar, P., Ruth, J. H., & Koch, A. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206337200 · Cited by 111
Sekharam, M., Zhao, H., Sun, M., Fang, Q., Zhang, Q., Yuan, Z., Dan, H. C., Boulware, D. C., Cheng, J. Q., & Coppola, D. (2003) · PubMed · Cited by 126
Self-citationLyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor Cells
Stettner, M. R., Wang, W., Nabors, B., Bharara, S., Flynn, D. C., Grammer, J. R., Gillespie, G. Y., & Gladson, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3688 · Cited by 111
Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., & Gray, N. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454126 · Cited by 107
“In support of this, it was shown that a subset of human colon cancer patients posses a mutant Src allele that lacks the negative-regulatory tyrosine phosphorylation site [18].”
BackgroundLung Cancer: Are we up to the Challenge?
Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010) · Current Genomics · doi:10.2174/138920210793175903 · Cited by 115
“The tyrosine kinase protein, SRC is also overexpressed and activated in epithelial tumors, and the levels of expression or activation generally correlate with disease progression [24], although activating mutations are rare [25].”
BackgroundEndosomal trafficking of Src tyrosine kinase
Sandilands, E., & Frame, M. C. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.05.004 · Cited by 109
Src signaling pathways in prostate cancer
Varkaris, A. S., Κατσιαμπούρα, Α., Araujo, J. C., Gallick, G. E., & Corn, P. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9481-1 · Cited by 118
“However, Src activating mutations are rarely found in human tumors, with the exception of a single report in colorectal cancer [23].”
BackgroundEmami, S., Floch, N. L., Bruyneel, E. A., Thim, L., May, F. E. B., Westley, B. R., Rio, M., Mareel, M. M. K., & Gespach, C. P. (2001) · The FASEB Journal · doi:10.1096/fj.00-0355com · Cited by 114
“Increased c-src protein expression and activating mutations in the carboxyl-terminal regulatory region of this nonreceptor tyrosine kinase are the critical molecular defects involved in src activation and colon cancer progression (43, 44).”
BackgroundChong, Y.-P., Mulhern, T. D., & Cheng, H.-C. (2005) · Growth Factors · doi:10.1080/08977190500178877 · Cited by 101
“The functional significance of the SH2 domain phospho-YT interaction in suppressing the activity of SFKs was confirmed by the discovery of an oncogenic mutation of c-Src in a group of patients with advanced metastatic colon carcinoma (Irby et al. 1999).”
BackgroundThe role of Src in solid and hematologic malignancies: Development of new‐generation Src inhibitors
Álvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Cancer · doi:10.1002/cncr.22215 · Cited by 118
“Irby et al.(41) identified a truncating mutation in cSrc at amino acid 531 in 12% of patients with advanced colon cancer and demonstrated that the mutation was activating, transforming, tumorigenic, and metastasis-promoting.”
BackgroundFujii, T., Koshikawa, K., Nomoto, S., Okochi, O., Kaneko, T., Inoue, S., Yatabe, Y., Takeda, S., & Nakao, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.03.029 · Cited by 112
Xing, L., Venegas, A. M., Chen, A. Y.-C., Garrett-Beal, L. J., Boyce, B. F., VARMUS, H. E., & Schwartzberg, P. L. (2001) · Genes & Development · doi:10.1101/gad.840301 · Cited by 111
“…defined as the normal cellular counterpart of the transforming gene of Rous Sarcoma Virus, c-src is overexpressed in a variety of human tumors, and an activating mutation has recently been found in a subpopulation of colon carcinomas (Bolen et al. 1987; Cartwright et al. 1989; Irby et al. 1999).”
BackgroundOneyama, C., Ikeda, J., Okuzaki, D., Suzuki, K., Kanou, T., Shintani, Y., Morii, E., Okumura, M., Aozasa, K., & Okada, M. (2011) · Oncogene · doi:10.1038/onc.2011.63 · Cited by 113
Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni, A., Marech, I., Silvestris, N., Vacca, A., & Lorusso, V. (2011) · Current Drug Targets · doi:10.2174/138945011794751591 · Cited by 103
“It is observed in metastatic tissues too together with activating mutations, which suggests a role of Src in the metastatic progression of colon tumours [88-90].”
Background
Metadata
- Authors
- Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- University of Calgary (CA)
- Corresponding author
- Yeatman, Timothy J.
- Venue
- Nature Genetics
- Published
- 1999-02
- Volume
- 21
- Issue
- 2
- Pages
- 187-190
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- DOI
- 10.1038/5971
- OpenAlex
- W1594706458
- Cited by
- 489
- References
- 28
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 2 · 2023: 11 · 2022: 1 · 2021: 5 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 19 · 2013: 12 · 2012: 21
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- National Institutes of Health (5k11ca065512-03)
- National Cancer Institute (R01CA055652, CA-55652, CA65512)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Src kinase, colon cancer, truncating mutations, non-receptor tyrosine kinase, oncogenic transformation, carcinogenesis, liver metastasis, malignant progression, Rous sarcoma virus
- MeSH terms
- Animals, Cell Line, Colonic Neoplasms, Humans, Liver Neoplasms, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Neoplasm Transplantation, Transfection, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Genes, src, Proto-Oncogene Proteins pp60(c-src), 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.